Literature DB >> 26348952

The payers' perspective on gene therapies.

Nicolas Touchot1, Mathias Flume2.   

Abstract

Mesh：

Year:  2015        PMID： 26348952     DOI： 10.1038/nbt.3332

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  3 in total

1.  Glybera's second act: the curtain rises on the high cost of therapy.

Authors:  Seppo Ylä-Herttuala
Journal:  Mol Ther       Date:  2015-02       Impact factor: 11.454

2.  The special case of gene therapy pricing.

Authors:  Troyen A Brennan; James M Wilson
Journal:  Nat Biotechnol       Date:  2014-09       Impact factor: 54.908

3.  Cost-effectiveness of sofosbuvir in the treatment of patients with hepatitis C.

Authors:  H Leleu; M Blachier; I Rosa
Journal:  J Viral Hepat       Date:  2014-09-15       Impact factor: 3.728
  3 in total
  6 in total

Review 1.  Genome editing and the next generation of antiviral therapy.

Authors:  Daniel Stone; Nixon Niyonzima; Keith R Jerome
Journal:  Hum Genet       Date:  2016-06-08       Impact factor: 4.132

2.  Ethical Hurdles in the Prioritization of Oncology Care.

Authors:  Folkert de Groot; Stefano Capri; Jean-Claude Castanier; David Cunningham; Bruno Flamion; Mathias Flume; Harald Herholz; Lars-Åke Levin; Oriol Solà-Morales; Christoph J Rupprecht; Natalie Shalet; Andrew Walker; Olivier Wong
Journal:  Appl Health Econ Health Policy       Date:  2017-04       Impact factor: 2.561

3.  DNA Delivery Systems Based on Peptide-Mimicking Cationic Lipids-The Effect of the Co-Lipid on the Structure and DNA Binding Capacity.

Authors:  Stephanie Tassler; Bodo Dobner; Lisa Lampp; Robert Ziółkowski; Elżbieta Malinowska; Christian Wölk; Gerald Brezesinski
Journal:  Langmuir       Date:  2019-03-19       Impact factor: 3.882

Review 4.  The state of gene therapy research in Africa, its significance and implications for the future.

Authors:  P Arbuthnot; M B Maepa; A Ely; M S Pepper
Journal:  Gene Ther       Date:  2017-07-10       Impact factor: 5.250

Review 5.  The impact of COVID-19 on the cell and gene therapies industry: disruptions, opportunities, and future prospects.

Authors:  Tingting Qiu; Yitong Wang; Shuyao Liang; Ru Han; Mondher Toumi
Journal:  Drug Discov Today       Date:  2021-04-20       Impact factor: 7.851

Review 6.  Gene therapy for monogenic liver diseases: clinical successes, current challenges and future prospects.

Authors:  Julien Baruteau; Simon N Waddington; Ian E Alexander; Paul Gissen
Journal:  J Inherit Metab Dis       Date:  2017-05-31       Impact factor: 4.982
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.